Embedded Files
DelveInsight's "Food Allergy Pipeline Analysis 2025" delivers extensive intelligence on over 25 pharmaceutical firms and more than 30 investigational medications within the Food Allergy development arena. The analysis encompasses profiles of Food Allergy therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Food Allergy pipeline therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.
Interested in recent developments within the Food Allergy Pipeline? Discover the emerging treatments and clinical studies generating attention @ Food Allergy Pipeline Outlook Report
Primary Highlights from the Food Allergy Pipeline Analysis
Primary Highlights from the Food Allergy Pipeline Analysis
On November 4, 2025, DBV Technologies initiated a Phase 3 investigation of 6-months duration to evaluate the safety profile of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).
DelveInsight's Food Allergy Pipeline analysis reveals a dynamic field featuring more than 25 engaged entities advancing over 30 investigational treatments for Food Allergy management.
Major Food Allergy pharmaceutical firms include DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, among additional organizations.
Notable Food Allergy investigational medications include Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib, among others.
Curious about which pharmaceutical companies are pioneering advancement in Food Allergy treatment? Explore comprehensive pipeline intelligence @ Food Allergy Clinical Trials Assessment
The Food Allergy Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Food Allergy.
Food Allergy Background
Food Allergy Background
Food allergies are adverse health effects arising from a specific immune response that emerges reproducibly upon exposure to a given food. These immune responses can range from mild to severe, potentially impacting the skin, gastrointestinal tract, respiratory, and cardiovascular systems. Food allergies are distinct from food intolerances, which do not engage the immune system and are generally less severe. The prevalence of food allergies has been increasing, especially in developed nations, with an estimated 5-8% of children and 1-2% of adults affected globally.
Food Allergy Investigational Drug Profiles
Food Allergy Investigational Drug Profiles
Viaskin Peanut: DBV Technologies
Viaskin Peanut (DBV712) is the novel therapeutic candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT Registered, DBV's method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The medication is presently under investigation in the Registration phase of development for managing peanut allergy.
PVX-108: Aravax
PVX108 is a next-generation, allergen-specific immunotherapy utilizing peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is engineered to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favorable safety profile for managing peanut allergic patients, including those with severe allergy. The medication is presently under investigation in the Phase II developmental stage for managing peanut allergy.
INT301: Intrommune Therapeutics
INT301 is an experimental oral mucosal immunotherapy (OMIT) product created by Intrommune Therapeutics for managing peanut allergy. It is a toothpaste-based formulation designed for daily use, delivering allergen proteins directly to the immune system via the oral mucosa to induce desensitization. Unlike traditional oral immunotherapy (OIT), INT301 aims to reduce allergic reactions with improved safety and convenience. The therapeutic candidate is presently in clinical development. The medication is presently under investigation in the Phase I developmental stage for managing peanut allergy.
Monitoring active Food Allergy Clinical investigations? This announcement is essential reading. Access the latest advances @ Food Allergy Treatment Drugs
The Food Allergy Pipeline Analysis Offers Intelligence On:
The Food Allergy Pipeline Analysis Offers Intelligence On:
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Food Allergy management, including cumulative therapies created by each organization for this indication.
It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Food Allergy Treatment.
Food Allergy pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.
Food Allergy investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Food Allergy market.
Food Allergy Pharmaceutical Firms
Food Allergy Pharmaceutical Firms
DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, among additional organizations.
The Food Allergy pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:
Intravenous
Subcutaneous
Oral
Intramuscular
Food Allergy products are classified under various molecular categories including:
Monoclonal antibody
Small molecule
Peptide
From investigational drug candidates to competitive intelligence, the Food Allergy Pipeline Analysis encompasses comprehensive insights - review it today @ Food Allergy Market Drivers and Barriers, and Future Perspectives
Scope of the Food Allergy Pipeline Analysis
Scope of the Food Allergy Pipeline Analysis
Coverage: Global
Food Allergy Pharmaceutical Firms: DBV Technologies, Aravax, Xencor, Novartis AG, Vedanta Biosciences, Alladapt Immunotherapeutics, Intrommune Therapeutics, IgGenix, Lapix Therapeutics, Neovacs, Inimmune, among additional organizations.
Food Allergy Investigational Treatments: Omalizumab, Acalabrutinib, Neffy, Adrenaline, RPT904, Montelukast, Remibrutinib, among others.
Food Allergy Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination
Food Allergy Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III
Stay informed in Healthcare Research - uncover future directions for the Food Allergy Treatment landscape through this comprehensive analysis @ Food Allergy Emerging Drugs and Major Players
Table of Contents
Table of Contents
* Introduction
* Executive Summary
* Food Allergy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Food Allergy- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Viaskin Peanut: DBV Technologies
* Mid Stage Products (Phase II)
* PVX-108: Aravax
* Early Stage Products (Phase I)
* INT301: Intrommune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Food Allergy Key Companies
* Food Allergy Key Products
* Food Allergy- Unmet Needs
* Food Allergy- Market Drivers and Barriers
* Food Allergy- Future Perspectives and Conclusion
* Food Allergy Analyst Views
* Food Allergy Key Companies
* Appendix
About Us
About Us
DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.
Contact Us
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Report abuse